Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus titration therapy in high-risk idiopathic membranous nephropathy
ChiCTR2400081948Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Mar 2024
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus in idiopathic membranous glomerulonephritis (IMG), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Remission rate at 24 weeks (CR + PR). Planned start Mar 2024; status: not yet recruiting.
02
Drugs
tacrolimus
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on ChiCTR2400081948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081948.